AI is moving from drug discovery into the daily running of trials, and it is reshaping the work faster than almost anyone expected.
For years, most AI investment in pharma sat upstream, in discovery. That has shifted. Agentic AI now reaches into trial execution itself: watching data across systems, drafting queries, flagging deviations, and surfacing the next best action. Industry estimates suggest a large share of routine clinical-operations tasks could be automated within the next few years.
What it means for the CRA. The parts of the role built on manual source-data review, query chasing, and report templating are the first to be automated. The CRA who thrives is the one who moves up the value chain: reading risk signals, coaching sites, deciding which deviations actually matter, and owning the human judgment a model cannot make. New titles are already appearing, from AI enabled CRA to digital trial manager. The role is becoming more analytical and less about volume.
What it means for companies. Adopting AI well is now a real advantage, and adopting it badly is a real risk. The questions that matter are practical: where does AI add genuine value, which tasks stay human, how is the model validated, and how do you keep every decision documented and accountable. Regulators are moving in step. The FDA published its Guiding Principles for AI in drug development in early 2026 and has begun deploying agentic AI internally, and the EMA has set out its own framework. The standard is clear: a human stays in the loop, and the rationale is always on record.
Where we come in. We help companies and CROs embed AI into clinical operations the right way, mapping where it helps, choosing the tools, and keeping quality and accountability intact. And we build it into our courses, so the professionals entering and growing in the field are ready for the work as it actually is now.
The shift is real, and it rewards the people and the companies who understand it early.